Chugai Pharmaceutical : Supplementary Materials Supplementary Materials

Delayed Japan Exchange			5-day change	1st Jan Change
8,845.00 ^JPY	-0.91%		+5.94%	+7.30%

Published on 04/24/2026
at 04:10 am EDT

Publicnow

‌Supplementary Materials

Consolidated Financial Statements for the three months ended March 31, 2026 (IFRS)

Notes: 1.

Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.

Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
Exchange rates used for each period are as follows.

Weighted average rate* (Yen)

Actual

Assumption

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

1-6

1-9

1-12

1-3

1-12

YTD

CHF

172.46

171.31

171.62

173.57

182.56

182.76

184.00

EUR

159.84

162.19

165.47

168.84

183.32

179.00

USD

147.35

146.56

146.36

147.08

149.85

151.05

151.00

SGD

113.62

111.63

112.44

113.61

122.22

119.00

*Weighted average of the exchange rates used to record foreign currency transactions included in categories from revenue to operating profit

Market average rate

Actual

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

1-6

1-9

1-12

YTD

CHF

169.60

172.12

175.95

179.98

200.23

EUR

160.38

162.03

165.29

168.68

183.63

USD

152.47

148.57

148.19

149.66

156.81

SGD

113.12

112.15

113.03

114.47

122.93

Period-end rate

Actual

FY2025

FY2026

Mar. 31

Jun. 30

Sep. 30

Dec. 31

Mar. 31

Jun. 30

Sep. 30

Dec. 31

CHF

170.10

181.00

186.38

197.48

199.66

EUR

162.24

169.46

174.31

183.75

183.01

USD

149.84

144.76

148.63

156.47

159.70

SGD

111.61

113.41

115.21

121.82

123.66

Reconciliation of IFRS results to Core results

(Billions of yen)

FY2025

FY2026

1-3

IFRS results

Intangible assets

Others

Core results

IFRS results

Intangible assets

Others

Core results

Revenue

288.5

–

288.5

321.7

–

321.7

Sales

259.7

–

259.7

291.6

–

291.6

Other revenue

28.7

–

28.7

30.2

–

30.2

Cost of sales

(87.8)

0.3

0.0

(87.5)

(92.8)

0.5

–

(92.3)

Gross profit

200.6

0.3

0.0

201.0

229.0

0.5

–

229.5

Research and development

(40.9)

0.2

0.0

(40.7)

(41.9)

0.0

–

(41.9)

Selling, general and administration

(23.2)

–

2.2

(21.0)

(28.9)

–

4.0

(24.9)

Other operating income (expense)

0.2

–

0.1

0.3

0.6

–

0.6

Operating profit

136.7

0.5

2.4

139.5

158.8

0.5

4.0

163.3

Financing costs

0.0

–

0.0

–

0.0

Other financial income (expense)

(0.8)

–

(0.8)

1.4

–

1.4

Profit before taxes

135.8

0.5

2.4

138.7

160.2

0.5

4.0

164.7

Income taxes

(38.6)

(0.1)

(0.7)

(39.5)

(44.8)

(0.2)

(1.2)

(46.2)

Net income

97.2

0.3

1.7

99.2

115.4

0.4

2.8

118.6

Attributable to

97.2

0.3

1.7

99.2

115.4

0.4

2.8

118.6

Chugai shareholders

97.2

0.3

1.7

99.2

115.4

0.4

2.8

118.6

Non-controlling interests

–

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai’s recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization （0.4 billion yen in 2025 and 0.5 billion yen in 2026) Impairment （0.1 billion yen in 2025 and None in 2026）

Others

Business rebuilding expenses （2.2 billion yen in 2025 and 4.0 billion yen in 2026） Restructuring expenses （0.1 billion yen in 2025 and None in 2026）

IFRS results (QTD)

(Billions of yen)

Actual

FY2025

FY2026

1-3

4-6

7-9

10-12

1-3

Change (%)

4-6

Change (%)

7-9

Change (%)

10-12

Change (%)

QTD

Revenue

288.5

290.0

333.2

346.3

321.7

+11.5

Sales

259.7

251.7

283.1

283.2

291.6

+12.3

Domestic

103.0

120.4

128.6

111.4

+8.2

Overseas

156.7

131.4

162.8

154.6

180.1

+14.9

Other revenue

28.7

38.3

50.0

63.1

30.2

+5.2

Royalty income and profit-sharing income

25.3

37.0

50.0

60.3

28.2

+11.5

of which income from Roche

24.5

35.5

47.3

56.0

24.1

(1.6)

Other operating income

3.4

1.3

(0.0)

2.7

1.9

(44.1)

Cost of sales

(87.8)

(88.1)

(100.2)

(87.6)

(92.8)

+5.7

(% of Sales)

33.8

35.0

35.4

30.9

31.8

–

Gross profit

200.6

201.9

232.9

258.7

229.0

+14.2

(% of Revenue)

69.5

69.6

69.9

74.7

71.2

–

Research and development

(40.9)

(45.7)

(48.6)

(52.4)

(41.9)

+2.4

(% of Revenue)

14.2

15.8

14.6

15.1

13.0

–

Selling, general and administration

(23.2)

(28.4)

(27.9)

(36.9)

(28.9)

+24.6

(% of Revenue)

8.0

9.8

8.4

10.7

9.0

–

Other operating income (expense)

0.2

8.8

0.0

(0.4)

0.6

+200.0

Operating profit

136.7

156.5

169.0

158.8

+16.2

(% of Revenue)

47.4

47.1

47.0

48.8

49.4

–

Financing costs

0.0

(0.1)

0.0

Other financial income (expense)

(0.8)

(0.6)

(0.4)

1.0

1.4

–

Profit before taxes

135.8

136.0

156.1

169.9

160.2

+18.0

(% of Revenue)

47.1

46.9

46.8

49.1

49.8

–

Income taxes

(38.6)

(38.8)

(44.9)

(41.5)

(44.8)

+16.1

Net income

97.2

111.2

128.4

115.4

+18.7

(% of Revenue)

33.7

33.5

33.4

37.1

35.9

–

Attributable to

Chugai shareholders

97.2

111.2

128.4

115.4

+18.7

Non-controlling interests

–

Earnings per share

Basic (yen)

59.09

59.04

67.58

78.03

70.13

+18.7

Diluted (yen)

59.08

59.03

67.58

78.02

70.13

+18.7

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

(Billions of yen)

Actual

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

Change (%)

1-6

Change (%)

1-9

Change (%)

1-12

Change (%)

YTD

Revenue

288.5

578.5

911.6

1,257.9

321.7

+11.5

Sales

259.7

511.4

794.6

1,077.8

291.6

+12.3

Domestic

103.0

223.3

343.7

472.4

111.4

+8.2

Overseas

156.7

288.1

450.9

605.4

180.1

+14.9

Other revenue

28.7

67.0

117.1

180.1

30.2

+5.2

Royalty income and profit-sharing income

25.3

62.3

112.3

172.7

28.2

+11.5

of which income from Roche

24.5

59.9

107.3

163.3

24.1

(1.6)

Other operating income

3.4

4.7

7.5

1.9

(44.1)

Cost of sales

(87.8)

(175.9)

(276.1)

(363.7)

(92.8)

+5.7

(% of Sales)

33.8

34.4

34.7

33.7

31.8

–

Gross profit

200.6

402.6

635.5

894.3

229.0

+14.2

(% of Revenue)

69.5

69.6

69.7

71.1

71.2

–

Research and development

(40.9)

(86.6)

(135.2)

(187.6)

(41.9)

+2.4

(% of Revenue)

14.2

15.0

14.8

14.9

13.0

–

Selling, general and administration

(23.2)

(51.6)

(79.5)

(116.5)

(28.9)

+24.6

(% of Revenue)

8.0

8.9

8.7

9.3

9.0

–

Other operating income (expense)

0.2

9.0

8.6

0.6

+200.0

Operating profit

136.7

273.3

429.8

598.8

158.8

+16.2

(% of Revenue)

47.4

47.2

47.1

47.6

49.4

–

Financing costs

0.0

(0.1)

(0.2)

0.0

Other financial income (expense)

(0.8)

(1.5)

(1.8)

(0.8)

1.4

–

Profit before taxes

135.8

271.8

427.9

597.8

160.2

+18.0

(% of Revenue)

47.1

47.0

46.9

47.5

49.8

–

Income taxes

(38.6)

(77.4)

(122.3)

(163.8)

(44.8)

+16.1

Net income

97.2

194.4

305.6

434.0

115.4

+18.7

(% of Revenue)

33.7

33.6

33.5

34.5

35.9

–

Attributable to

Chugai shareholders

97.2

194.4

305.6

434.0

115.4

+18.7

Non-controlling interests

–

Earnings per share

Basic (yen)

59.09

118.13

185.70

263.73

70.13

+18.7

Diluted (yen)

59.08

118.12

185.70

263.72

70.13

+18.7

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (QTD)

(Billions of yen)

Actual

FY2025

FY2026

1-3

4-6

7-9

10-12

1-3

Change (%)

4-6

Change (%)

7-9

Change (%)

10-12

Change (%)

QTD

Revenue

288.5

290.0

333.2

346.3

321.7

+11.5

Sales

259.7

251.7

283.1

283.2

291.6

+12.3

Domestic

103.0

120.4

128.6

111.4

+8.2

Overseas

156.7

131.4

162.8

154.6

180.1

+14.9

Other revenue

28.7

38.3

50.0

63.1

30.2

+5.2

Royalty income and profit-sharing income

25.3

37.0

50.0

60.3

28.2

+11.5

of which income from Roche

24.5

35.5

47.3

56.0

24.1

(1.6)

Other operating income

3.4

1.3

(0.0) 2.7

1.9

(44.1)

Cost of sales

(87.5)

(87.7)

(88.2)

(92.3)

+5.5

(% of Sales)

33.7

34.8

31.2

31.1

31.7

–

Gross profit

201.0

202.3

245.0

258.1

229.5

+14.2

(% of Revenue)

69.7

69.8

73.5

74.5

71.3

–

Research and development

(40.7)

(45.5)

(42.6)

(51.2)

(41.9)

+2.9

(% of Revenue)

14.1

15.7

12.8

14.8

13.0

–

Selling, general and administration

(21.0)

(24.4)

(24.0)

(33.8)

(24.9)

+18.6

(% of Revenue)

7.3

8.4

7.2

9.8

7.7

–

Other operating income (expense)

0.3

0.1

0.0

(0.4)

0.6

+100.0

Operating profit

139.5

132.5

178.5

172.7

163.3

+17.1

(% of Revenue)

48.4

45.7

53.6

49.9

50.8

–

Financing costs

0.0

(0.1)

0.0

Other financial income (expense)

(0.8)

(0.6)

(0.4)

1.0

1.4

–

Profit before taxes

138.7

131.8

178.1

173.6

164.7

+18.7

(% of Revenue)

48.1

45.4

53.5

50.1

51.2

–

Income taxes

(39.5)

(37.6)

(51.6)

(42.6)

(46.2)

+17.0

Net income

99.2

94.3

126.5

131.0

118.6

+19.6

(% of Revenue)

34.4

32.5

38.0

37.8

36.9

–

Attributable to

Chugai shareholders

99.2

94.3

126.5

131.0

118.6

+19.6

Non-controlling interests

–

Core earnings per share (diluted) (yen)

60.30

57.27

76.87

79.58

72.03

+19.5

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share. Other financial income (expense) includes net amount of FX related gains/losses.

Core results (YTD)

(Billions of yen)

Actual

Forecast (Jan 29th announced)

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

Change (%)

1-6

Change (%)

1-9

Change (%)

1-12

Change (%)

1-12

Change (%)

YTD

Revenue

288.5

578.5

911.6

1,257.9

321.7

+11.5

1,345.0

+6.9

Sales

259.7

511.4

794.6

1,077.8

291.6

+12.3

1,100.0

+2.1

Domestic

103.0

223.3

343.7

472.4

111.4

+8.2

498.0

+5.4

Overseas

156.7

288.1

450.9

605.4

180.1

+14.9

602.0

(0.6)

Other revenue

28.7

67.0

117.1

180.1

30.2

+5.2

245.0

+36.0

Royalty income and profit-sharing income

25.3

62.3

112.3

172.7

28.2

+11.5

217.2

+25.8

of which income from Roche

24.5

59.9

107.3

163.3

24.1

(1.6)

178.5

+9.3

Other operating income

3.4

4.7

7.5

1.9

(44.1)

27.8

+270.7

Cost of sales

(87.5)

(175.2)

(263.3)

(351.5)

(92.3)

+5.5

(383.5)

+9.1

(% of Sales)

33.7

34.3

33.1

32.6

31.7

–

34.9

–

Gross profit

201.0

403.3

648.3

906.5

229.5

+14.2

961.5

+6.1

(% of Revenue)

69.7

71.1

72.1

71.3

–

71.5

–

Research and development

(40.7)

(86.3)

(128.8)

(180.1)

(41.9)

+2.9

(190.0)

+5.5

(% of Revenue)

14.1

14.9

14.1

14.3

13.0

–

14.1

–

Selling, general and administration

(21.0)

(45.4)

(69.4)

(103.2)

(24.9)

+18.6

(102.0)

(1.2)

(% of Revenue)

7.3

7.8

7.6

8.2

7.7

–

7.6

–

Other operating income (expense)

0.3

0.4

0.0

0.6

+100.0

0.5

–

Operating profit

139.5

272.0

450.5

623.2

163.3

+17.1

670.0

+7.5

(% of Revenue)

48.4

47.0

49.4

49.5

50.8

–

49.8

–

Financing costs

0.0

(0.1)

(0.2)

0.0

Other financial income (expense)

(0.8)

(1.5)

(1.8)

(0.8)

1.4

–

Profit before taxes

138.7

270.5

448.6

622.2

164.7

+18.7

(% of Revenue)

48.1

46.8

49.2

49.5

51.2

–

Income taxes

(39.5)

(77.0)

(128.6)

(171.2)

(46.2)

+17.0

Net income

99.2

193.5

320.0

451.0

118.6

+19.6

485.0

+7.5

(% of Revenue)

34.4

33.4

35.1

35.9

36.9

–

36.1

–

Attributable to

Chugai shareholders

99.2

193.5

320.0

451.0

118.6

+19.6

Non-controlling interests

–

Weighted average number of shares in issue used

to calculate diluted earnings per share (Millions of shares)

1,646

0.0

Core earnings per share (diluted) (yen)

60.30

117.57

194.44

274.02

72.03

+19.5

295.00

+7.7

Core payout ratio (%)

99.3

44.7

–

Dividend per share (Full year) (yen)

272

132

–

Dividend per share (Year end) (yen)

147

–

Dividend per share (Half year) (yen)

125

–

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

The annual dividend per share for the year ended December 31, 2025 consists of a regular dividend of 122 yen (half-year: 50 yen, year-end: 72 yen) and a special dividend for the company’s 100th Anniversary of 150 yen (half-year: 75 yen, year-end: 75 yen).

Core statements of revenue (QTD)

(Billions of yen)

Actual

FY2025

FY2026

1-3

4-6

7-9

10-12

1-3

Change (%)

4-6

Change (%)

7-9

Change (%)

10-12

Change (%)

QTD

Sales

259.7

251.7

283.1

283.2

291.6

+12.3

Domestic

103.0

120.4

128.6

111.4

+8.2

Oncology

53.1

63.5

64.1

65.8

55.7

+4.9

Tecentriq

13.8

16.1

16.8

13.8

0.0

Polivy

7.5

9.4

10.0

10.2

9.3

+24.0

Phesgo

6.8

8.6

9.1

9.4

8.4

+23.5

Alecensa

7.5

8.2

8.6

9.2

7.8

+4.0

Lunsumio

0.0

0.9

1.2

1.1

1.2

–

Kadcyla

3.5

4.3

4.2

4.3

3.7

+5.7

Avastin

6.1

6.9

6.6

6.5

4.3

(29.5)

Perjeta

3.0

3.4

3.2

3.0

2.4

(20.0)

Foundation Medicine

2.0

1.9

2.2

1.9

1.8

(10.0)

Other products

2.9

3.7

2.9

3.5

3.0

+3.4

Specialty

49.9

56.8

56.3

62.8

55.7

+11.6

Hemlibra

12.6

16.4

15.7

18.0

14.6

+15.9

Actemra

10.9

12.9

13.0

13.8

11.8

+8.3

Enspryng

6.1

7.1

7.6

8.3

6.9

+13.1

Vabysmo

5.4

6.6

7.7

7.4

+37.0

Evrysdi

3.4

4.5

4.1

4.2

3.6

+5.9

Elevidys

–

0.5

–

PiaSky

1.3

1.7

1.8

2.0

2.1

+61.5

CellCept

2.0

2.2

1.8

2.0

1.7

(15.0)

Other products

8.2

5.4

5.8

6.8

6.9

(15.9)

Tamiflu

2.3

0.0

0.2

0.0

–

Overseas

156.7

131.4

162.8

154.6

180.1

+14.9

Hemlibra

86.2

64.5

103.9

89.8

108.9

+26.3

To Roche

85.0

63.3

102.8

88.3

107.3

+26.2

Actemra

42.5

44.4

32.1

39.1

39.5

(7.1)

To Roche

41.3

43.1

30.8

37.6

38.2

(7.5)

Alecensa

17.4

11.7

16.9

13.2

17.0

(2.3)

To Roche

16.6

11.0

16.1

12.4

16.2

(2.4)

Enspryng

3.1

2.9

2.6

(0.0)

–

To Roche

3.0

2.8

2.5

(0.1)

–

Neutrogin

2.4

2.2

2.1

2.2

2.1

(12.5)

Sigmart

2.2

2.3

1.7

2.1

(4.5)

Other products

2.9

3.3

2.9

5.8

10.5

+262.1

Other revenue

28.7

38.3

50.0

63.1

30.2

+5.2

Revenue

288.5

290.0

333.2

346.3

321.7

+11.5

Domestic

103.4

121.2

120.6

128.8

111.6

+7.9

Overseas

185.1

168.9

212.7

217.5

210.1

+13.5

Core statements of revenue (YTD)

(Billions of yen)

Actual

Forecast

(Jan 29th announced)

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

Change (%)

1-6

Change (%)

1-9

Change (%)

1-12

Change (%)

1-12

Change (%)

YTD

Sales

259.7

511.4

794.6

1,077.8

291.6

+12.3

1,100.0

+2.1

Domestic

103.0

223.3

343.7

472.4

111.4

+8.2

498.0

+5.4

Oncology

53.1

116.6

180.7

246.5

55.7

+4.9

259.2

+5.2

Tecentriq

13.8

29.9

46.0

62.8

13.8

0.0

61.1

(2.7)

Polivy

7.5

17.0

27.0

37.2

9.3

+24.0

42.5

+14.2

Phesgo

6.8

15.4

24.5

33.9

8.4

+23.5

35.1

+3.5

Alecensa

7.5

15.8

24.3

33.5

7.8

+4.0

32.8

(2.1)

Lunsumio

0.0

1.0

2.2

3.3

1.2

–

28.4

+760.6

Kadcyla

3.5

7.8

11.9

16.3

3.7

+5.7

16.5

+1.2

Avastin

6.1

13.0

19.6

26.1

4.3

(29.5)

13.7

(47.5)

Perjeta

3.0

6.3

9.6

12.5

2.4

(20.0)

11.1

(11.2)

Foundation Medicine

2.0

3.9

6.0

7.9

1.8

(10.0)

7.8

(1.3)

Other products

2.9

6.7

9.6

13.0

3.0

+3.4

10.1

(22.3)

Specialty

49.9

106.7

163.0

225.8

55.7

+11.6

238.8

+5.8

Hemlibra

12.6

29.1

44.7

62.7

14.6

+15.9

66.6

+6.2

Actemra

10.9

23.8

36.7

50.5

11.8

+8.3

46.2

(8.5)

Enspryng

6.1

13.3

20.9

29.2

6.9

+13.1

31.9

+9.2

Vabysmo

5.4

12.0

18.5

26.2

7.4

+37.0

30.1

+14.9

Evrysdi

3.4

7.9

12.0

16.2

3.6

+5.9

15.2

(6.2)

Elevidys

–

0.5

–

12.0

–

PiaSky

1.3

3.0

4.8

6.9

2.1

+61.5

8.3

+20.3

CellCept

2.0

4.2

6.0

8.0

1.7

(15.0)

7.1

(11.3)

Other products

8.2

13.5

19.3

26.1

6.9

(15.9)

21.3

(18.4)

Tamiflu

2.3

2.5

0.0

–

2.7

+8.0

Overseas

156.7

288.1

450.9

605.4

180.1

+14.9

602.0

(0.6)

Hemlibra

86.2

150.7

254.6

344.5

108.9

+26.3

354.0

+2.8

To Roche

85.0

148.3

251.0

339.3

107.3

+26.2

347.2

+2.3

Actemra

42.5

86.9

119.0

158.2

39.5

(7.1)

136.3

(13.8)

To Roche

41.3

84.5

115.2

152.9

38.2

(7.5)

130.8

(14.5)

Alecensa

17.4

29.1

46.0

59.2

17.0

(2.3)

60.4

+2.0

To Roche

16.6

27.5

43.6

56.0

16.2

(2.4)

57.1

+2.0

Enspryng

3.1

6.1

8.6

11.3

(0.0)

–

9.2

(18.6)

To Roche

3.0

5.9

8.4

10.9

(0.1)

–

8.6

(21.1)

Neutrogin

2.4

4.6

6.7

8.9

2.1

(12.5)

7.0

(21.3)

Sigmart

2.2

4.5

6.7

8.5

2.1

(4.5)

2.4

(71.8)

Other products

2.9

6.3

9.2

15.0

10.5

+262.1

32.6

+117.3

Other revenue

28.7

67.0

117.1

180.1

30.2

+5.2

245.0

+36.0

Revenue

288.5

578.5

911.6

1,257.9

321.7

+11.5

1,345.0

+6.9

Domestic

103.4

224.4

344.9

473.8

111.6

+7.9

500.5

+5.6

Overseas

185.1

354.0

566.6

784.1

210.1

+13.5

844.5

+7.7

Financial position

(Billions of yen)

		Actual				Actual
		FY2025				FY2026
		Mar. 31	Jun. 30	Sep. 30	Dec. 31	Mar. 31	vs. Mar. 31, 2025	vs. Dec. 31, 2025	Jun. 30	vs. Jun. 30, 2025	vs. Dec. 31, 2025	Sep. 30	vs. Sep. 30, 2025	vs. Dec. 31, 2025	Dec. 31	vs. Dec. 31, 2025
Trade accounts receivable		252.1	261.1	287.2	317.5	301.7	49.6	(15.8)
Inventories		233.1	235.5	246.3	276.8	288.3	55.2	11.5
Trade accounts payable		(22.0)	(43.1)	(45.2)	(89.2)	(78.7)	(56.7)	10.5
Other net working capital		(56.2)	(11.9)	(19.6)	21.9	(38.7)	17.5	(60.6)
Net working capital		407.0	441.7	468.7	527.0	472.6	65.6	(54.4)
Property, plant and equipment		448.5	456.8	449.6	456.6	459.5	11.0	2.9
Right-of-use assets		15.1	14.6	13.5	22.9	22.2	7.1	(0.7)
Intangible assets		17.3	33.3	34.2	54.5	58.5	41.2	4.0
Other long-term assets – net		40.8	45.3	45.0	49.3	52.9	12.1	3.6
Long-term net operating assets		521.7	549.9	542.3	583.3	593.1	71.4	9.8
Net operating assets		928.7	991.5	1,011.0	1,110.3	1,065.7	137.0	(44.6)
Debt		–	–	–	–	–	–	–
Marketable securities		521.1	530.5	426.0	553.1	432.1	(89.0)	(121.0)
Cash and cash equivalents		423.4	497.1	456.4	426.6	418.0	(5.4)	(8.6)
Net cash		944.6	1,027.6	882.4	979.7	850.1	(94.5)	(129.6)
Other non-operating assets – net		33.9	(34.0)	(3.3)	(64.3)	(8.0)	(41.9)	56.3
Net non-operating assets		978.5	993.6	879.2	915.4	842.1	(136.4)	(73.3)
Total net assets		1,907.2	1,985.1	1,890.1	2,025.7	1,907.7	0.5	(118.0)

Total net assets
	Total assets	2,139.5	2,278.3	2,183.6	2,468.6	2,265.1	125.6	(203.5)
	Total liabilities	(232.3)	(293.2)	(293.5)	(442.9)	(357.4)	(125.1)	85.5
Attributable to
	Chugai shareholders	1,907.2	1,985.1	1,890.1	2,025.7	1,907.7	0.5	(118.0)
	Non-controlling interests	–	–	–	–	–	–	–

Trade accounts receivable: trade receivable and notes receivable Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Cash flows

(Billions of yen)

Actual

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

1-6

1-9

1-12

YTD

Operating profit – IFRS basis

136.7

273.3

429.8

598.8

158.8

Depreciation and impairment of property, plant and equipment

6.1

12.3

30.2

35.8

6.6

Depreciation and impairment of right-of-use assets

1.4

2.9

4.4

6.0

1.6

Amortization and impairment of intangible assets

0.5

0.9

1.3

3.3

0.6

Other cash adjustment on operating profit

1.5

0.4

7.1

7.6

2.1

Operating profit, net of operating cash adjustments

146.2

289.8

472.9

651.5

169.6

(Increase) decrease in trade accounts receivable

6.0

(2.6)

(28.6)

(58.5)

15.8

(Increase) decrease in inventories

7.5

4.2

(7.3)

(36.7)

(13.2)

Increase (decrease) in trade accounts payable

6.4

27.3

29.3

72.7

(10.7)

Change in other net working capital etc.

20.9

(12.8)

(10.9)

(57.1)

64.7

Total (increase) decrease in net working capital etc.

40.8

16.1

(17.5)

(79.7)

56.7

Investment in property, plant and equipment

(22.0)

(48.9)

(58.9)

(76.3)

(12.7)

Lease liabilities paid

(2.0)

(4.0)

(5.9)

(8.2)

(2.5)

Investment in intangible assets

(0.5)

(16.2)

(17.3)

(35.3)

(7.9)

Operating free cash flows

162.4

236.8

373.2

452.1

203.3

as % of Revenue

56.3%

40.9%

35.9%

63.2%

Treasury activities (interest income/expenses, foreign exchange gains/losses etc.)

(12.8)

(6.7)

(1.3)

12.3

(1.8)

Tax paid

(106.9)

(107.2)

(190.7)

(191.1)

(89.3)

Free cash flows

42.7

122.8

181.2

273.3

112.2

Dividends paid

(93.4)

(93.8)

(299.5)

(299.4)

(242.0)

Transaction in own equity instruments

0.1

Net effect of currency translation on net cash

(1.2)

2.1

4.3

9.4

0.2

Net change in net cash

(51.7)

31.3

(113.9)

(16.6)

(129.6)

Other cash adjustment on operating profit: Adjustments for all non-cash income and expense items other than amortization expenses and impairment included in

operating profit (such as loss on inventory differences, allowance for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in provisions) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and utilization of provisions.

Operating free cash flow (Operating FCF): Pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF. Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent. Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Key Performance Indicators

Units

Actual

Forecast

(Jan 29th announced)

FY2025

FY2026

1-3

1-6

1-9

1-12

1-3

1-6

1-9

1-12

As of Mar. 31

As of Jun. 30

As of Sep. 30

As of Dec. 31

As of Mar. 31

As of Jun. 30

As of Sep. 30

As of Dec. 31

Total indicator

Core return on invested capital (Core ROIC)

10.7

20.1

32.9

43.9

10.8

Return on invested capital (ROIC)

10.5

20.2

31.4

42.3

10.5

Ratio of profit to total assets (ROA)

4.5

8.7

13.9

18.6

4.9

Ratio of equity attributable to Chugai shareholders

89.1

87.1

86.6

82.1

84.2

Ratio of equity attributable to

Chugai shareholders (stock price base)

523.0

543.5

486.0

549.5

625.7

Price book value ratio (PBR)

times

5.9

6.2

5.6

6.7

7.4

Ratio of net income to equity attributable to Chugai shareholders (ROE)

5.1

10.0

16.1

22.1

5.9

Margin indicator (Core)

ROS

48.4

47.0

49.4

49.5

50.7

49.8

COS ratio (vs. Prod. sales)

33.7

34.2

33.1

32.6

31.7

34.9

R&D cost ratio

14.1

14.9

14.1

14.3

13.0

14.1

Selling, general and administration cost ratio

7.3

7.8

7.6

8.2

7.7

7.6

Turnover indicator

Total asset turnover

13.3

25.8

41.5

53.8

13.6

Working capital turnover

30.7

59.7

93.1

122.2

29.6

Inventory turnover

Months

8.0

9.1

9.3

Receivables turnover

Months

2.9

3.1

3.3

3.5

3.1

Payables turnover

Months

0.7

1.5

2.9

2.5

Fixed asset turnover

61.4

120.0

190.6

253.2

59.9

PP&E turnover

65.4

130.0

206.5

282.8

70.2

Intangible assets turnover

1,639.5

2,261.4

3,504.1

3,474.6

569.3

Dividend / per stock indicator

Dividends per share (Half year)

Yen

125

Dividends per share (Year end)

Yen

147

Dividends per share (Full year)

Yen

272

132

Core earnings per share (diluted)

Yen

60.30

117.57

194.44

274.02

72.03

295.00

Core payout ratio (%)

99.3

44.7

Equity per share attributable to Chugai shareholders (BPS)

Yen

1,158.97

1,206.25

1,148.51

1,230.91

1,159.17

Ratio of dividends to equity attributable to

Chugai shareholders (DOE)

22.8

Cashflow indicator

Cash conversion cycle (CCC)

Months

10.1

9.6

9.8

9.7

9.9

Net cash turnover period

Months

9.8

10.7

8.7

9.3

7.9

Number of employees

7,726

7,972

7,923

7,872

7,805

Investment on property, plant and equipment

Billions of yen

23.8

38.9

49.7

63.4

9.7

68.0

Depreciation

Billions of yen

6.1

12.3

18.5

25.0

6.6

27.0

Investment on intangible assets

Billions of yen

–

16.3

17.6

39.9

4.5

Amortization

Billions of yen

0.5

0.9

1.2

1.6

0.6

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes) ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes) ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenue / Total asset, CCC：[Trade accounts receivable/Sales＋（Inventories – Trade accounts payable）/Cost of sales]* passed months Net cash turnover period: Net cash/Revenue * passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized. The adjusted figures are used for calculating average NOA for Core ROIC and ROIC.

‌Development Pipeline [Main table] (as of March 31, 2026)

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Projected submission

Mode of Action Modality (Dosage form)

Partner

Filed

AF802/RG7853

in-house

alectinib Alecensa

ALK fusion / rearrangement gene-positive unresectable advanced or recurrent solid

tumors #

Japan

June 2025

ALK inhibitor

Small molecule (oral)

–

RG7446

Roche

atezolizumab Tecentriq

Adjuvant therapy for MRD-positive bladder cancer #

Japan

January 2026

Engineered anti-PD-L1 monoclonal antibody Antibody (IV)

–

RG435

Roche

bevacizumab Avastin

Neurofibromatosis type 2 (NF2) #

Japan

August 2025

Anti-VEGF humanized monoclonal antibody Antibody (IV)

–

Phase III

AF802/RG7853

in-house

alectinib Alecensa

Maintenance treatment of NSCLC (stage III) after chemoradiotherapy #

Global

–

ALK inhibitor

Small molecule (oral)

Roche

RG7446

Roche

atezolizumab Tecentriq

HCC (intermediate stage) # (Avastin) #

Japan

2027

Engineered anti-PD-L1 monoclonal antibody Antibody (IV)

Roche

RG6171

Roche

giredestrant

–

Breast cancer (adjuvant)

Japan

2026

SERD (Selective Estrogen Receptor Degrader)

Small molecule (Oral)

Roche

Breast cancer (1st Line)

(palbociclib)

Japan

－*

Roche

Breast cancer (1st Line-3rd Line)

(everolimus)

Japan

2026

Roche

RG7828

Roche

mosunetuzumab Lunsumio

Follicular lymphoma (2nd Line) # (lenalidomide)

Japan

2026

Anti-CD20/CD3 bispecific antibody

Antibody (IV)

Roche

Previously untreated follicular lymphoma #

Japan

2029 and beyond

Roche

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Projected submission

Mode of Action Modality (Dosage form)

Partner

RG6026

Roche

glofitamab

–

Previously untreated large B-cell lymphoma

(Polivy)

Japan

2028

Anti-CD20/CD3 bispecific antibody

Antibody (IV)

Roche

RG6330

Roche

divarasib

–

NSCLC (2nd Line)

Japan

2027

KRAS G12C inhibitor

Small molecule (Oral)

Roche

NSCLC (1st Line)

Japan

2029 and beyond

Roche

RG6114

Roche

inavolisib

–

PIK3CA-mutated, HER2-positive breast cancer (1st Line)

(Phesgo)

Japan

2028

PI3Kα inhibitor

Small molecule (oral)

Roche

PIK3CA-mutated breast cancer (endocrine-sensitive) (1st Line)

(CDK4/6 inhibitor + letrozole)

Japan

2028

Roche

RG7159

Roche

obinutuzumab Gazyva

Lupus nephritis #

Japan

2026

Glycoengineered type II anti-CD20 monoclonal Antibody

Antibody (IV)

Nippon

shinyaku

Nephrotic syndrome #

Japan

2026

Nippon shinyaku

Extra renal lupus #

Japan

2027

Nippon

shinyaku

RG6299/ASO factor B Roche

sefaxersen

–

IgA nephropathy

Japan

2029 and beyond

Antisense oligonucleotide targeting complement factor B mRNA

Nucleic acid (SC)

Roche

RG6631

Roche

afimkibart

–

Ulcerative colitis

Japan

2027

Anti-TL1A antibody Antibody (-)

Roche

Crohn’s disease

Japan

2029 and beyond

Roche

–

Renalys Pharma

sparsentan

–

IgA nephropathy

Japan

2026

Dual endothelin

/angiotensin II receptor antagonist

Small molecule (Oral)

–

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Projected submission

Mode of Action Modality (Dosage form)

Partner

SA237/RG6168

in-house

satralizumab Enspryng

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) #

Global

2026

pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody

Antibody (SC)

Roche

Autoimmune encephalitis (AIE) #

Global

2027

Roche

RG6102

Roche

trontinemab

–

Alzheimer’s disease

Japan

2029 and beyond

Anti-amyloid beta/TfR1 fusion protein

Antibody (IV)

Roche

RG6356/SRP-9001

Roche

delandistrogene moxeparvovec Elevidys

Duchenne muscular dystrophy (DMD) (non-ambulatory) #

Japan

2029 and beyond

Microdystrophin gene therapy

Gene therapy (IV)

Sarepta**

SKY59/RG6107

in-house

crovalimab PiaSky

Atypical hemolytic uremic syndrome (aHUS) #

Global

2026

Anti-C5 recycling antibody

Antibody (SC)

Roche

ACE910/RG6013

In-house

emicizumab Hemlibra

Type 3 von Willebrand disease #

Global

2027

Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody

Antibody (SC)

Roche

SA237/RG6168

in-house

satralizumab Enspryng

Thyroid eye disease (TED) #

Global

2026

pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody

Antibody (SC)

Roche

RG6179

Roche

vamikibart

–

Noninfectious uveitic macular edema (UME)

Japan

2026

Anti-IL-6 monoclonal antibody

Antibody (vitreous

injection)

Roche

RG7716

Roche

faricimab Vabysmo

Non-proliferative diabetic retinopathy (NPDR) #

Japan

2028

Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous

injection)

–

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Projected submission

Mode of Action Modality (Dosage form)

Partner

RG6615

Roche

zilebesiran

–

Hypertension

Japan

2029 and beyond

RNAi therapeutic targeting angiotensinogen (AGT)

RNAi (SC)

Alnylam Pharmace uticals

Phase II

RG6026

Roche

glofitamab

–

Relapsed or refractory diffuse large B-cell lymphoma

Japan

2026

Anti-CD20/CD3 bispecific antibody

Antibody (IV)

–

Relapsed or refractory mantle cell lymphoma

Japan

2028

–

RG6042

Roche

tominersen

–

Huntington’s disease

Japan

–

Antisense oligonucleotide targeting HTT mRNA Nucleic acid (IV)

Roche

GYM329/RG6237

In-house

emugrobart

–

Obesity

Global

2029 and beyond

Anti-latent myostatin

sweeping antibody Antibody (SC)

Roche

Phase l/II

RG6114

Roche

inavolisib

–

PIK3CA-mutated breast cancer (endocrine-resistant) (palbociclib + fulvestrant)

Japan

–

PI3Kα inhibitor

Small molecule (Oral)

Roche

NXT007/RG6512

in-house

–

Hemophilia A

Global

2028

Anti-coagulation factor IXa/X bispecific antibody Antibody (SC)

Roche

RG6321

Roche

ranibizumab (Port Delivery Platform with ranibizumab)***

–

Neovascular age-related macular degeneration

Japan

2026

Humanized anti-VEGF monoclonal antibody Fragment Fab Antibody (injection via implant)

–

Diabetic macular edema

Japan

2026

–

Phase l

GC33

in-house

codrituzumab

–

HCC

Global

–

Anti-Glypican-3 humanized monoclonal antibody

Antibody (IV)

–

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Projected submission

Mode of Action Modality (Dosage form)

Partner

ALPS12

in-house

clesitamig

–

Solid tumors

Global

–

Anti-DLL3/CD3/CD137

trispecific antibody Antibody (IV)

–

ROSE12

in-house

–

Solid tumors

Global

–

Anti-CTLA-4 Switch antibody

Antibody (IV)

–

MINT91

in-house

–

Solid tumors

Global

–

Small molecule (Oral)

–

AUBE00

In-house

–

Solid tumors

Global

–

Pan-KRAS inhibitor Macrocyclic peptide (Oral)

–

RG7421

Roche

cobimetinib

–

Solid tumors

Japan

–

MEK inhibitor

Small molecule (Oral)

–

RG6160

Roche

cevostamab

–

Relapsed or refractory multiple myeloma

Japan

–

Anti-FcRH5/CD3 bispecific antibody

Antibody (IV)

–

DONQ52

in-house

–

Celiac disease

Global

–

Anti-HLA-DQ2.5/gluten peptides multispecific antibody

Antibody (SC)

–

RAY121

in-house

–

Autoimmune disease

Global

–

Anti-C1s recycling antibody

Antibody (SC)

–

RG7935

Roche

prasinezumab

–

Parkinson’s disease

Japan

–

Anti-α-synuclein

monoclonal antibody Antibody (IV)

–

REVN24

in-house

–

Acute diseases

Global

–

Small molecule (IV)

–

RAY121

in-house

–

Global

–

Anti-C1s recycling antibody

Antibody (-)

–

Development Discontinued

Development code Licensor

Generic name Product name

Indication

# Additional indication (Combination drug)

Country/region

Development stage

Mode of Action Modality (Dosage form)

Partner

RG7446

Roche

atezolizumab Tecentriq

HCC (2nd Line) # (lenvatinib or sorafenib)

Japan

Phase III

Engineered anti-PD-L1 monoclonal antibody Antibody (IV)

Roche

GYM329/RG6237

in-house

emugrobart

–

Spinal muscular atrophy (SMA)

(Evrysdi)

Global

Phase II/III

Anti-latent myostatin sweeping antibody Antibody (SC)

Roche

Facioscapulohumeral muscular dystrophy (FSHD)

Global

Phase II

SA237/RG6168

in-house

satralizumab Enspryng

Duchenne muscular dystrophy (DMD) #

Global

Phase II

pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody

Antibody (SC)

Roche

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies. The treatment lines and target segments described in the indication section are based on the currently ongoing clinical trials and do not represent the final wording on the package insert.

*Removed from the pipeline at the FY2026.12 Q1 Financial Results announcement ** Sarepta manages the global study including Japan ***The medical device component (ocular implant and ancillary devices) was filed in Japan in March 2026

Changes from the last announcement on January 29, 2026

Oncology

-RG7828 Filed (Relapsed or refractory large B-cell lymphoma (combination with Polivy)) → Approved

-RG6114 Phase III (PIK3CA-mutated, HER2-positive breast cancer (1st Line) (combination with Phesgo): development started)

-RG6114 Phase III (PIK3CA-mutated breast cancer (endocrine-sensitive) (1st Line) (combination with CDK4/6 inhibitor and letrozole): development started)

-RG7446 Phase III (HCC (2nd Line) (combination with lenvatinib or sorafenib)) → Development discontinued Neuroscience

-GYM329/RG6237 Phase II/III (Spinal muscular atrophy (SMA) (combination with Evrysdi)) → Development discontinued

-GYM329/RG6237 Phase II (Facioscapulohumeral muscular dystrophy (FSHD)) → Development discontinued

-Enspryng Phase II (Duchenne muscular dystrophy (DMD)) → Development discontinued

Development Pipeline [Attached table]

(Major Chugai originated projects licensed out to 3rd parties excluding Roche) (as of March 31, 2026)

Development code licensee/In-house

Generic name Product name

Indication

# Additional Indication (combination)

Stage Country/region

Mode of Action Modality (Dosage form)

Licensee (Granted rights )

VS-6766/CKI27

avutometinib AVMAPKI

KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) (defactinib)

Phase III

Overseas, U.S.

RAF/MEK clamp Small molecule (Oral)

Verastem Oncology

(exclusive global license for the manufacturing, development and marketing)

Phase II Japan

Metastatic pancreatic ductal adenocarcinoma (mPDAC) (1st line) (defactinib+chemotherapy)

Phase I/II U.S.

– /CIM331

nemolizumab NEMLUVIO

Chronic pruritus of unknown origin (CPUO)

Phase II

Overseas

Anti-IL-31 receptor A humanized monoclonal antibody

Antibody (SC)

Galderma

(exclusive global license for the development and marketing excluding Japan)

LY3502970/OWL833

orforglipron

–

Type 2 diabetes

Phase III Global Filed

Oral non-peptidic GLP-1 receptor agonist

Small molecule (Oral)

Eli Lilly and Company (worldwide development and commercialization rights)

Obesity

Phase III Global Filed

U.S., EU, Japan

Obstructive sleep apnea

Phase III Global

Hypertension

Phase III Global

Osteoarthritis

Phase III Global

Stress urinary incontinence

Phase III Global

Investigation of the effect of orforglipron on the incidence of major adverse cardiovascular events*

Phase III Global

Peripheral arterial disease

Phase III Global

AP306/EOS789

–

Hyperphosphatemia

Phase II China

Oral inhibitor of phosphate transporters Small molecule (Oral)

Alebund Pharmaceuticals (exclusive global license for the manufacturing, development and marketing)

The treatment lines and target segments described in the indication section are based on the currently ongoing clinical trials and do not represent the final wording on the package insert.

*In Participants with established atherosclerotic cardiovascular disease and/or chronic kidney disease

Progress made in R&D activities of major Chugai originated projects licensed out to 3rd party excluding Roche during the period from January 1, 2026 to March 31, 2026 was as follows.

– Eli Lilly and Company started a global Phase III study for the oral non-peptidic GLP-1 receptor agonist LY3502970/OWL833 (orforglipron) for the treatment of peripheral arterial disease in Q1 2026. In addition, it has filed for approval to the European Medicines Agency for the treatment of type 2 diabetes and obesity in Q1 2026.

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of March 31, 2026)

Development Request

Product

Indication

Development Status

Fourth development request

Xeloda*

Neuroendocrine tumor

Submitted company opinion and waiting for evaluation by committee

Avastin

Cerebral edema induced by radiation necrosis

Submitted company opinion and waiting for evaluation by committee

Mircera

Anemia associated with chronic kidney disease (CKD) in pediatric patients 3 months of age and older

Submitted company opinion and waiting for evaluation by committee

*Transferred the marketing authorization holder to CHEPLAPHARM K.K. as of February 1, 2024

Major Clinical Trials

Project

Expected indication

Study design

Study name

Stage

CT information

Oncology

AF802/RG7853

(Alecensa)

Maintenance treatment of NSCLC (stage III) after chemoradiotherapy

ALK fusion-positive: Alecensa vs. durvalumab

HORIZON01

Phase III

NCT05170204

RG7446

(Tecentriq)

HCC (intermediate stage)

Tecentriq + Avastin + TACE vs. TACE

TALENTACE

Phase III

NCT04712643

RG6171/SERD

(giredestrant)

Breast cancer (adjuvant)

HR positive: RG6171 vs. endocrine therapy

lidERA

Phase III

NCT04961996

Breast cancer [1st line]

HR positive: RG6171 + palbocicilib vs. letrozole + palbocicilib

persevERA

Phase III

NCT04546009

Breast cancer [1st line-3rd line]

HR positive: RG6171 + everolimus vs. endocrine therapy+ everolimus

evERA

Phase III

NCT05306340

RG7828

(Lunsumio)

Follicular lymphoma [2nd line]

Lunsumio + lenalidomide vs. Rituxan + lenalidomide

CELESTIMO

Phase III

NCT04712097

Previously untreated follicular lymphoma

Lunsumio + lenalidomide vs. Rituxan + chemotherapy

–

Phase III (domestic)

jRCT2011240017

RG6026

(glofitamab)

Previously untreated large B-cell lymphoma

RG6026 + Polivy + Rituxan + chemotherapy vs. Polivy + Rituxan + chemotherapy

SKYGLO

Phase III

NCT06047080

Relapsed or refractory diffuse large B-cell lymphoma

RG6026 + gemcitabine + oxaliplatin (GemOx) (single arm)

–

Phase II (domestic)

jRCT2051250036

Relapsed or refractory mantle cell lymphoma

RG6026 (single arm)

RG6330

(divarasib)

NSCLC [2nd line]

RG6330 vs. sotorasib or adagrasib

Krascendo 1

Phase III

NCT06497556

NSCLC [1st line]

RG6330 + pembrolizumab vs. pembrolizumab +chemotherapy

Krascendo 2

Phase III

NCT06793215

RG6114

(inavolisib)

PIK3CA-mutated, HER2-positive breast cancer (1st Line)

RG6114 + Phesgo vs Placebo + Phesgo

INAVO122

Phase III

NCT05894239

PIK3CA-mutated breast cancer (endocrine-sensitive) (1st Line)

RG6114 + CDK4/6 Inhibitor + letrozole vs Placebo + CDK4/6 Inhibitor + letrozole

INAVO123

Phase III

NCT06790693

PIK3CA-mutated breast cancer (endocrine-resistant)

RG6114 + palbociclib + fulvestrant (single arm)

–

Phase I/II (domestic)

jRCT2031250161

Immunology

RG7159

(Gazyva)

Lupus nephritis

Standard of care treatment ± Gazyva

–

Phase III (domestic)

jRCT2011210059

Project

Expected indication

Study design

Study name

Stage

CT information

Nephrotic syndrome

Gazyva vs. MMF

INShore

Phase III

NCT05627557

Extra renal lupus

Gazyva vs. Placebo

–

Phase III (domestic)

jRCT2071230031

RG6299

(sefaxersen)

IgA nephropathy

RG6299 vs. Placebo

IMAGINATION

Phase III

NCT05797610

RG6631

(afimkibart)

Ulcerative colitis

RG6631 vs. Placebo

Ametrine-1

Phase III

NCT06589986

Crohn’s disease

RG6631 vs. Placebo

SIBERITE-1

Phase III

NCT06819878

sparsentan

IgA nephropathy

sparsentan (single arm)

–

Phase III

(domestic)

jRCT2051240070

Neuroscience

SA237/RG6168

(Enspryng)

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

Enspryng vs. Placebo

METEOROID

Phase III

NCT05271409

Autoimmune encephalitis (AIE)

Enspryng vs. Placebo

CIELO

Phase III

NCT05503264

RG6356/SRP-9001

(delandistrogene moxeparvovec)

Duchenne muscular dystrophy (DMD) (non-ambulatory)

RG6356 vs. Placebo

ENVISION

Phase III

NCT05881408

RG6102

(trontinemab)

Alzheimer’s disease

RG6102 vs. Placebo

TRONTIER 1/ TRONTIER 2

Phase III

NCT07169578 NCT07170150

Hematology

SKY59/RG6107

(PiaSky)

Atypical hemolytic uremic syndrome (aHUS)

PiaSky (single arm)

COMMUTE-a

Phase III

NCT04861259

PiaSky (single arm)

COMMUTE-p

Phase III

NCT04958265

ACE910/RG6013

(Hemlibra)

Type 3 von Willebrand disease

Hemlibra vs. On-demand therapy (standard of care treatment)

WILL-EMI

Phase III

NCT06998524

Ophthalmology

SA237/RG6168

(Enspryng)

Thyroid eye disease (TED)

Enspryng vs. Placebo

SatraGO-1/ SatraGO-2

Phase III

NCT05987423 NCT06106828

RG6179

(vamikibart)

Noninfectious uveitic macular edema

RG6179 vs. sham

Sandcat

Phase III

NCT05642325

Project

Expected indication

Study design

Study name

Stage

CT information

RG7716

(Vabysmo)

Non-proliferative diabetic retinopathy

RG7716 vs. sham

AZUSA

Phase III (domestic)

jRCT2071250009

RG6321

(ranibizumab (Port Delivery Platform with ranibizumab))

Neovascular age-related macular degeneration / Diabetic macular edema

RG6321 (single arm)

TEIEN

Phase I/II (domestic)

jRCT2071210073

Other diseases

RG6615

(zilebesiran)

Hypertension

RG6615 vs. Placebo

ZENITH

Phase III

NCT07181109

The treatment lines and target segments described in the indication section are based on the currently ongoing clinical trials and do not represent the final wording on the package insert.

Clinical Trials of In-House Developed Projects

Excluding projects listed in Major Clinical Trials among the projects listed in the development pipeline. Only clinical trials led by Chugai or Roche are listed.

Project

Expected indication

Stage

Enrollment*

as of March 31, 2026

Study start

CT information

Oncology

GC33

HCC

Phase I

November, 2008

NCT00746317

Phase I

October, 2009

NCT00976170

Phase I (domestic)

October, 2010

jRCT2080221218

Phase II

185

May, 2012

NCT01507168

Phase I

August, 2016

jRCT2080223270

ALPS12

(clesitamig)

Solid tumors

Phase I

122

October, 2025

NCT07107490

ROSE12

Solid tumors

Phase Ia/Ib

219

June, 2023

NCT05907980

MINT91

Solid tumors

Phase I

122

April, 2025

jRCT2031240713

AUBE00

Solid tumors

Phase I

130

June, 2025

jRCT2031250094

Immunology

DONQ52

Celiac disease

Phase Ia/Ib

September, 2022

NCT05425446

Phase Ic

July, 2024

ACTRN12624000316505

RAY121

Autoimmune disease

Phase Ib

144

August, 2024

NCT06723106

Project

Expected indication

Stage

Enrollment*

as of March 31, 2026

Study start

CT information

Hematology

NXT007/RG6512

Hemophilia A

Phase I/II (domestic)

124

August, 2019

jRCT2080224835

Phase I

(domestic) (only healthy adults)

May, 2022

jRCT2031220050

Phase I/II

October, 2023

NCT05987449

Other diseases

REVN24

Acute diseases

Phase I

(domestic) (only healthy adults)

210

October, 2023

jRCT2071230074

RAY121

–

Phase I

(only healthy adults)

March, 2025

2024-515151-38-00

GYM329/RG6237

(emugrobart)

Obesity

Phase II

285

May, 2025

NCT06965413

* The number of enrollments is listed based on public information and generally refers to estimations or actual results.

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of March 31, 2026)

Alterations

Cancer type

Relevant drugs

Activating EGFR alterations

NSCLC

afatinib, erlotinib, gefitinib, osimertinib, dacomitinib

EGFR exon 20 T790M alteration

osimertinib

ALK fusion genes

alectinib, crizotinib, ceritinib, brigatinib

ROS1 fusion genes

entrectinib

MET exon 14 skipping alterations

capmatinib

BRAF V600E and V600K alterations

Malignant melanoma

dabrafenib, trametinib, vemurafenib, encorafenib, binimetinib

BRAF V600 alterations and BRAF fusion genes

Glioma

tovorafenib

ERBB2 copy number alterations (HER2 gene

amplification positive)

Breast cancer

trastuzumab

AKT1 alterations

capivasertib

PIK3CA alterations

PTEN alterations

KRAS/NRAS wildtype

Colorectal cancer

cetuximab, panitumumab

Microsatellite instability-high

nivolumab

Microsatellite instability-high

Solid tumors

pembrolizumab

Tumor mutational burden-high

pembrolizumab

NTRK1/2/3 fusion genes

entrectinib, larotrectinib, repotrectinib

RET fusion genes

selpercatinib

ALK fusion genes

alectinib

BRCA1/2 alterations

Ovarian cancer

olaparib

BRCA1/2 alterations

Prostate cancer

olaparib, talazoparib

FGFR2 fusion genes

Biliary tract cancer

pemigatinib

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval, or in the process of completing approval related procedures.

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of March 31, 2026)

Alterations

Cancer type

Relevant drugs

Activating EGFR alterations

NSCLC

afatinib, erlotinib, gefitinib, osimertinib

EGFR exon 20 T790M alteration

osimertinib

ALK fusion genes

alectinib, crizotinib, ceritinib

ROS1 fusion genes

entrectinib

MET exon 14 skipping alterations

capmatinib

NTRK1/2/3 fusion genes

Solid tumors

entrectinib

BRCA1/2 alterations

Prostate cancer

olaparib

Attachments

Original document
Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on April 24, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2026 at 08:09 UTC.

Apr. 16	Eli Lilly and Company Announces Positive Topline Results from Phase 3 Achieve-4 Trial Evaluating Foundayo (Orforglipron) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight At Increased Cardiovascular Risk	CI
Apr. 09	Foundayo? (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S	CI
Apr. 06	Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 9,100 Yen from 7,500 Yen, Keeps at Hold	MT
Apr. 02	Japan’s Nikkei rallies on efforts to reopen critical oil shipping lane	RE
Mar. 23	Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 In Spinal Muscular Atrophy And Facioscapulohumeral Muscular Dystrophy	CI
Mar. 23	Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says	DJ
Mar. 23	Japan Shares Decline On Currency Concerns, Oil Speculation Warning	MT
Mar. 23	Chugai Pharmaceutical to Discontinue GYM329 for Neuromuscular Diseases After Mid-Stage Failures	MT
Mar. 22	Chugai’s Emugrobart Study Discontinued for Neuromuscular Conditions; Obesity Trials Unaffected	MT
Mar. 18	Nikkei ends nearly 3% higher as AI, chip stocks rally	RE
Mar. 17	Nikkei jumps nearly 2% as AI, chip stocks rally	RE
Feb. 24	Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan	CI
Feb. 24	Sarepta Therapeutics Says Elevidys Available in Japan for Duchenne Muscular Dystrophy	MT
Feb. 24	Sarepta Therapeutics announces commercial launch of Elevidys in Japan	RE
Feb. 06	Japan’s Nikkei rallies on earnings in unsteady trade before Sunday election	RE

Duration

Period

Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.